Novartis top of pile in European pharma in 2020, say Jefferi...

Jefferies’ team of analysts have recently been touting Roche as their favourite big European pharma – but going into 2020 it’s Novartis that gets the strongest “buy” rating in a broker note

GSK files multiple myeloma drug with FDA after phase 2 succe...

GSK has filed for FDA approval of its potential first-in-class multiple myeloma drug belantamab mafodotin for relapsed/refractory multiple myeloma on the basis of a set of strong results fr

GSK leanest with R&D spend in big pharma - but gets bang for...

GlaxoSmithKline’s CEO Emma Walmsley has made great play of her company’s new approach to R&D under the leadership of its guru Hal Barron.

Chasing Mylan, Hikma tries again with rejected generic Advai...

GSK must continue to improve R&D, says CEO Walmsley

It’s been two and a half years since Emma Walmsley took over as CEO of GlaxoSmithKline, and at the time was seen as the protégé of her predecessor Sir Andrew Witty.

Shingrix and Trelegy shield GSK from Advair fallout